A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 21, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
DRUG

Atezolizumab

Atezolizumab will be administered IV.

DRUG

Tiragolumab

Tiragolumab will be administered IV.

DRUG

Placebo

Placebo will be administered IV.

Trial Locations (40)

106

National Taiwan University Cancer Center, Zhongzheng Dist.

407

Taichung Veterans General Hospital, Taichung

824

E-DA Hospital, Kaohsiung City

3168

Monash Health, Clayton

4575

Sunshine Coast University Hospital, Birtinya

10300

Vajira Hospital, Bangkok

16247

St. Vincent's Hospital, Gyeonggi-do

34147

Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma Hastanesi, Tibbi Onkoloji, Bakirkoy / Istanbul

37019

Ospedale P. Pederzoli Casa di cura Privata, Peschiera Del Garda (VR)

41404

Kyungpook National University Chilgok Hospital, Daegu

50612

Pusan National University Yangsan Hospital, Gyeongsangnam-do

110042

Liaoning Provincial Cancer Hospital, Shengyang

210008

Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing

213003

Changzhou First People's Hospital, Changzhou

250117

Shandong Cancer Hospital, Jinan

300060

Tianjin Cancer Hospital, Tianjin

310022

Zhejiang Cancer Hospital, Zhejiang

430030

Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

450052

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

510080

Guangdong General Hospital, Guangzhou

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou

650118

Yunnan Cancer Hospital, Kunming

C1426AGE

Centro Oncologico Korben, Ciudad Autonoma Buenos Aires

60336-232

Crio - Centro Regional Integrado de Oncologia, Fortaleza

40170-380

Nucleo de Oncologia da Bahia - NOB, Salvador, Bahia

99010-260

Hospital de Clínicas de Passo Fundo, Passo Fundo

91350-200

Hospital Nossa Senhora da Conceicao, Porto Alegre

14784-400

Hospital de Cancer de Barretos, Barretos

01509-010

Hospital A. C. Camargo, São Paulo

DUMMY_VALUE

Ningbo No.2 Hospital, Ningbo

734-8551

Hiroshima University Hospital, Hiroshima

589-8511

Kindai University Hospital, Osaka

01-138

Instytut Gruzlicy I Chorob Pluc, Warsaw

602-739

Pusan National University Hospital, Busan

463-707

Seoul National University Bundang Hospital, Seongnam-si

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Yonsei University Health System, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

08308

Korea University Guro Hospital, Seoul

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT06267001 - A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy | Biotech Hunter | Biotech Hunter